Clinical Trial

Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid Tumors

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2024 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the safety and efficacy of CAR-T/CAR-NK cells in patients with recurrent or unresectable solid tumors, including pancreatic cancer, prostate cancer, breast cancer, glioma, etc
Trial Details
NCT Number NCT06572956
Lead Sponsor The Second Hospital of Shandong University
Conditions Safety and Efficacy of Cellular Drugs, Objective Response Rate of Subjects, Etc
Enrollment 10 participants
Start Date 2024-03-21
Primary Completion 2025-03-01 (estimated)
Study Completion 2025-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-27